Discovery of T-Type Calcium Channel Antagonist from Multicomponent Reactions and their Application in Paclitaxel-Induced Peripheral Neuropathy

Case ID:

This invention uses innovative selective T-type antagonists in order to ease pain involved with chemotherapy-induced peripheral neuropathy (CIPN).


Chemotherapy remains a frontline treatment for many forms of cancer, however, chemotherapy agents commonly cause severe side effects such as CIPN. While opioids have been used to manage CIPN, the side effects of opioid use are often more overbearing than their benefits. CIPN is found in 64% of cancer patients from the beginning to the end phase of the cancer cycle and no effective treatments currently exist for CIPN-specific pain. This invention utilizes calcium antagonists to create a novel pain relief method for cancer patients experience CIPN.



  • Chronic pain market
  • Cancer treatments



  • Mediate analgesic effects
  • Non-opioid based alternative
  • Targets T-type Ca channels for pain management
Patent Information:
Contact For More Information:
Garrett Edmunds
Licensing Manager, UAHS-TLA
The University of Arizona
Lead Inventor(s):
Jun Wang
Rajesh Khanna